ClinicalTrials.gg
CompletedNCT07176208Updated Sep 30, 2026

Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adults

A Phase 1 interventional study of 5 mg Dronabinol (Marinol®) + Placebo Beverage and 10 mg Dronabinol (Marinol®) + Placebo Beverage in Cannabis, Drug Effects and Driving Performance, sponsored by Food and Drug Administration (FDA). Completed at 2 sites in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Food and Drug Administration (FDA) · Phase 1, Interventional, and Other

How we know

Updated Sep 30, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

With the increasing prevalence and use of cannabis products by the public, there exists a need to better understand the safety impact of cannabis use, particularly when it comes to subjective perceptions of drug effect and driving impairment. This study aims to evaluate the dose-dependent effects of oral Δ9-THC alone and in combination with alcohol (0.08% BAC [Blood Alcohol Concentration]) on driving performance and subjective feeling in healthy adults. The results of this study will address current knowledge gaps on the effects of oral Δ9-THC on driving impairment across a clinically relevant dose range.

Read the detailed description

The cannabis plant contains bioactive compounds known as cannabinoids, with delta-9 tetrahydrocannabidiol (Δ9-THC) and cannabidiol (CBD) being the most well-known cannabinoids in varieties of cannabis. With the increasing prevalence and use of cannabis products by the public, there exists a need to better understand the safety impact of cannabis use, particularly when it comes to subjective perceptions of drug effect and driving impairment. Studies have evaluated the effects of Δ9-THC on perception and driving capacity, however they have largely focused on inhaled routes of administration in experienced users and at relatively high doses. Research on the impact of oral Δ9-THC use in occasional users at lower doses (10 mg and below) on driving capacity is limited. Furthermore, despite the increasing prevalence of concurrent cannabis and alcohol use, there also remains a significant gap in research examining the combined effects of oral THC and alcohol on driving performance. This study aims to evaluate the dose-dependent effects of oral Δ9-THC alone and in combination with alcohol (0.08% BAC [Blood Alcohol Concentration]) on driving performance and subjective feeling in healthy adults. These effects will also be compared to the established alcohol-related impairment benchmark of blood alcohol content (0.08% BAC). The inclusion of an alcohol-only arm targeting 0.08% BAC will serve as a relevant positive control, representing the legal intoxication threshold in most states in the USA and providing a well-characterized impairment baseline against which THC and THC/alcohol combination effects can be measured. The results of this study will address current knowledge gaps on the effects of oral Δ9-THC on driving impairment across a clinically relevant dose range.

In this randomized, double-blind, 6-period crossover study, 48 healthy adult volunteers with driving experience and previous cannabis exposure will receive single oral doses across six treatment conditions: 5 mg THC, 10 mg THC, 5 mg THC combined with alcohol (target BAC of 0.08%), 10 mg THC combined with alcohol (target BAC of 0.08%), alcohol alone (target BAC of 0.08%), and matched placebo, with washout periods between treatments. The study will evaluate the dose-dependent effects of Δ9-THC (with and without alcohol) on both objective driving performance and subjective participant experience. Objectives primarily include standardized driving simulator assessments measuring standard deviation of lateral position (SDLP) and standard deviation of speed (SDSP), as well as subjective effects measured through use of Visual Analogue Scales (VAS). Assessments will be conducted at baseline and predetermined intervals post-dose over 24 hours.

02

Conditions studied

  • Cannabis, Drug Effects
  • Driving Performance

Keywords

  • delta-9-tetrahydrocannabinol
  • Cannabis drug effects
  • Driving Performance
  • Subjective Perception
  • THC and alcohol
03

In context

Lead sponsor

Food and Drug Administration (FDA) is the lead sponsor of 25 studies on the registry; 2 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 13 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects who meet all the following inclusion criteria will be eligible to participate in the study:

  1. Subject signs an IRB approved written and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act authorization) before any study related procedures are performed.
  2. Subject is a healthy, non-smoking man or woman, 21 to 55 years of age, inclusive, who weighs at least 50 kg (110 lbs) and has a of 18.5 to 33.0 kg/m2, inclusive, at Screening and check-in (Day -1).
  3. Subject possesses a valid U.S. driver's license and has driven a minimum of 600 miles per year for the previous 3 years.
  4. During screening subjects will be assessed using a driving simulation test. Subject must not demonstrate any motion sickness as determined by the investigator and defined in the driving simulation operations manual and subject must not have erratic driving as defined in the Screening Visit Driving Practice Assessment Operational Manual.
  5. Subject has normal medical history findings, clinical laboratory results, vital sign measurements, 12-lead results, and physical examination findings at screening and check-ins or, if abnormal, the abnormality is not considered (as determined and documented by the investigator or designee). Out of range tests may be repeated once for confirmation at screening and/or check-ins at investigator's discretion.
  6. Subject is an occasional user of cannabis, defined as having at least one cannabis exposure within the last 6 months, but no daily use pattern and no cannabis exposure within the past month.
  7. Subject has consumed alcohol equivalent to achieving approximately 0.10% BAC (approximately 3-4 standard drinks for females and 4-5 drinks for males over 1-2 hours) within the past year without experiencing significant adverse reactions. (Note: 1 standard drink = 12 ounces of beer [5% alcohol by volume], 5 ounces of wine [12% alcohol by volume], or 1.5 ounce of distilled spirits [40% alcohol]).
  8. Subject must report at least 1 instance of simultaneous alcohol and cannabis use over the past one year without experiencing significant adverse reactions based on investigator discretion.
  9. Participants must agree to refrain from using any of the following for the duration of the study: alcohol, nicotine containing products, marijuana (except for provided study drug) or marijuana-derived products, hemp or hemp-derived products, including CBD, and illicit drugs of any kind. Only THC and alcohol administered at the study site will be permitted.
  10. Subject must test negative for severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) by a rapid antigen test at check-in. If a subject's test comes back as invalid, the test can be repeated.
  11. Female subjects must be of non- (non-childbearing potential includes females defined as spontaneous amenorrhea for at least 12 months with FSH in the post-menopausal range or females who have undergone a surgical procedure that prevents pregnancy (e.g., hysterectomy, bilateral tubal ligation, occlusion, or salpingo-oophorectomy) or, if they are of childbearing potential, they must have negative serum HCG at screening and check-in and be practicing 2 effective methods of (as determined by the investigator or designee; only one of the methods, but not both, may be a barrier technique) from Screening until at least 3 months after the end of the study. They must agree not to donate eggs for 30 days until after study completion.
  12. Male subjects must agree to practice 2 effective methods of birth control (as determined by the investigator or designee) beginning at check-in (Day -1) until at least 3 months after the last dose of study drug. Subject must also agree to inform female partner(s) about participation in the study and ensure they are using a highly effective form of contraception (e.g., hormonal birth control or copper IUD). Male subjects may not donate sperm for 3 months following the last dose of study drug.
  13. Subject agrees to and is highly likely (as determined by the investigator) to comply with the protocol defined procedures and to complete the study.

Exclusion criteria

Exclusion Criteria

Subjects who meet any of the following exclusion criteria will not be eligible to participate in the study:

  1. A history of cannabis use disorder or use of any psychoactive drug in the last month.
  2. Any reported history of alcohol intolerance.
  3. Alcohol intolerance as detected by ethanol patch testing.
  4. Subject has a dry mouth or history of salivary gland disfunction or surgery.
  5. A history of any psychiatric diagnosis, including mood, anxiety, and psychotic disorders.
  6. Any family history of schizophrenia or other psychotic illness.
  7. Any history of seizures, epilepsy, or traumatic brain injury.
  8. History of syncope within 3 months prior to screening or any history of recurrent and/or unexplained episodes of syncope.
  9. A positive test result for alcohol and drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, alcohol, opiates, phencyclidine, propoxyphene, methadone, ) at screening and check-in (Day -1).
  10. Use or intend to use any medications other than , including prescription, OTC, herbal or recreational products (excluding cannabis) in the 14 days prior to check-in (Day -1), unless deemed acceptable by the investigator.
  11. Currently participating in another clinical study of an drug or has been treated with any investigational drug within 30 days or 5 half-lives (whichever is longer) of dosing for this study.
  12. Subject has used nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, electronic cigarettes) within 6 weeks of Screening. Subjects must refrain from using these throughout the study.
  13. Subject is unable to tolerate a controlled, quiet study conduct environment, including avoidance of music, television, movies, games, and activities that may cause excitement, emotional tension, or arousal during the prespecified time points.
  14. Subject has known or suspected allergies or sensitivities to the study drug, delta 9-THC or sesame seeds/oil.
  15. Subjects will be excluded if they meet criteria for alcohol use disorder based on alcohol abuse screening or exceed monthly consumption thresholds (no more than 8 standard drinks/month for females and no more than 16 standard drinks/month for males and no more than 14 units of standard drinks per week within 6 months before Screening), or has a history of alcohol use disorder or drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12 ounces of beer, 5 ounces of wine, or 1.5 ounce of spirits/hard liquor).
  16. Subject has a history of suicidal ideation or previous suicide attempts.
  17. Subject has a history or evidence of a disorder, condition, or disease (e.g., cancer, [HIV], hepatic or renal impairment) that, in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
  18. Subject has a diagnosis of COVID-19 or any signs or symptoms that are consistent with COVID-19 per CDC recommendations at screening or check-in (Day -1). These include subjects with fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, diarrhea, or other symptoms indicative of likely COVID-19 in the opinion of the investigator.
  19. Subject has any condition possibly affecting study drug absorption (e.g., gastrectomy, Crohn's disease, irritable bowel syndrome).
  20. Subject has clinical laboratory test results (hematology, serum chemistry and urinalysis) at screening or check-ins that are outside the reference ranges provided by the clinical laboratory and considered clinically significant by the investigator. Out of range tests may be repeated once for confirmation at screening and/or check-ins at investigator's discretion.
  21. Subject has a mean systolic blood pressure \<90 or >140 mmHg or a mean diastolic blood pressure \<50 or >90 mmHg at either screening or check-ins, unless determined not clinically significant per investigator. Blood pressure will be measured after the subject has been resting in a sitting position for approximately 5 minutes. Two blood pressure repeats will be permitted in instances where initial measures out of normal range and the average of the three readings will be used to determine eligibility.
  22. Subject has a positive test result at screening for HIV 1 or 2 antibody, virus antibodies, or surface antigen.
  23. Subject is unable or unwilling to undergo multiple venipunctures for blood sample collection because of poor tolerability or is unlikely to complete the study due to poor venous access.
  24. Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days, or donated plasma within 7 days before check-in.
  25. Subject with any visual or hearing impairment that will prevent accurate completion of study assessments (as determined by the investigator).
  26. Subject has any other condition that precludes his or her participation in the study (as determined by the investigator).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Treatment A - 5 mg Δ9-THC + Placebo beverage

    Subjects in this arm will receive one 5 mg oral dose of THC and a placebo beverage

    Drug: 5 mg Dronabinol (Marinol®) + Placebo Beverage

  • Experimental
    Treatment B - 10 mg Δ9-THC + Placebo beverage

    Subjects in this arm will receive one 10 mg oral dose of THC and a placebo beverage

    Drug: 10 mg Dronabinol (Marinol®) + Placebo Beverage

  • Experimental
    Treatment C - 5 mg Δ9-THC + Alcohol beverage with BAC target of 0.08%

    Subjects in this arm will receive one 5 mg oral dose of THC and an alcohol beverage targeting a blood alcohol concentration (BAC) of 0.08%

    Drug: 5 mg Dronabinol (Marinol®) + Alcohol Beverage

  • Experimental
    Treatment D - 10 mg Δ9-THC + Alcohol beverage with BAC target of 0.08%

    Subjects in this arm will receive one 10 mg oral dose of THC and an alcohol beverage targeting a blood alcohol concentration (BAC) of 0.08%

    Drug: 10 mg Dronabinol (Marinol®) + Alcohol Beverage

  • Active comparator
    Treatment E - Placebo capsule + Alcohol beverage with BAC target of 0.08%

    Subjects in this arm will receive one placebo capsule and an alcohol beverage targeting a blood alcohol concentration (BAC) of 0.08% as a positive control

    Drug: Placebo Capsule + Alcohol Beverage

  • Placebo comparator
    Treatment F - Placebo capsule + Placebo beverage

    Subjects in this arm will receive one placebo capsule and a placebo beverage

    Drug: Placebo Capsule + Placebo Beverage

Interventions

  • Drug5 mg Dronabinol (Marinol®) + Placebo Beverage

    Subjects in this arm will receive one dose of 5 mg THC (Dronabinol) with a placebo beverage in one of the assigned treatment days.

  • Drug10 mg Dronabinol (Marinol®) + Placebo Beverage

    Subjects in this arm will receive one dose of 10 mg THC (Dronabinol) with a placebo beverage in one of the assigned treatment days.

  • Drug5 mg Dronabinol (Marinol®) + Alcohol Beverage

    Drug page: DronabinolStudies of DronabinolDronabinol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects in this arm will receive one dose of 5 mg THC (Dronabinol) with an alcoholic beverage (to achieve a target BAC of 0.08%) in one of the assigned treatment days.

  • Drug10 mg Dronabinol (Marinol®) + Alcohol Beverage

    Drug page: DronabinolStudies of DronabinolDronabinol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects in this arm will receive one dose of 10 mg THC (Dronabinol) with an alcoholic beverage (to achieve a target BAC of 0.08%) in one of the assigned treatment days.

  • DrugPlacebo Capsule + Alcohol Beverage

    Subjects in this arm will receive placebo capsule with an alcoholic beverage (to achieve a target BAC of 0.08%) in one of the assigned treatment days.

  • DrugPlacebo Capsule + Placebo Beverage

    Subjects in this arm will receive a placebo capsule with a placebo beverage in one of the assigned treatment days.

06

What researchers measure

Primary outcomes

  1. Simulated driving performance as measured by Standard Deviation of Lateral Position (SDLP) after Δ9-THC administration alone or in combination with alcohol compared to alcohol alone.

    Simulated driving performance will be measured by the endpoint standard deviation of lateral position (SDLP) using a STISIM (model M4000-R) driving simulator after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to active control (alcohol alone).

    Time frame: Up to 8 hours after study drug administration.

Secondary outcomes

  1. Simulated driving performance as measured by Standard Deviation of Lateral Position (SDLP) after Δ9-THC administration alone or in combination with alcohol compared to placebo.

    Simulated driving performance will be measured by the endpoint standard deviation of lateral position (SDLP) using a STISIM (model M4000-R) driving simulator after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to placebo.

    Time frame: Up to 8 hours after study drug administration.

  2. Simulated driving performance as measured by Standard Deviation of Speed Position (SDSP) after Δ9-THC administration alone or in combination with alcohol compared to placebo.

    Simulated driving performance will be measured by the endpoint standard deviation of speed position (SDSP) using a STISIM (model M4000-R) driving simulator after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to placebo.

    Time frame: Up to 8 hours after study drug administration.

  3. Simulated driving performance as measured by Standard Deviation of Speed Position (SDSP) after Δ9-THC administration alone or in combination with alcohol compared to alcohol alone.

    Simulated driving performance will be measured by the endpoint standard deviation of speed position (SDSP) using a STISIM (model M4000-R) driving simulator after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to alcohol alone.

    Time frame: Up to 8 hours after study drug administration.

  4. Maximum subjective self-rated driving impairment after Δ9-THC administration alone or in combination with alcohol compared to placebo.

    Maximum subjective self-rated driving impairment after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to placebo will be measured by the VAS question (VAS "drug driving impairment"): "How much did the study drug affect your driving?"

    Time frame: Up to 24 hours after study drug administration.

  5. Maximum subjective feeling state of VAS "Drug Effect" after Δ9-THC administration alone or in combination with alcohol compared to placebo.

    Maximum subjective feeling state of VAS "Drug Effect" after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to placebo will be measured by the VAS question (VAS "Drug Effect"): "Are you feeling a drug effect right now?"

    Time frame: Up to 24 hours after study drug administration.

  6. Maximum subjective feeling state of VAS "Willingness to Drive" after Δ9-THC administration alone or in combination with alcohol compared to placebo.

    Maximum subjective feeling state of VAS "Willingness to Drive" after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to placebo will be measured by the VAS question (VAS "Willingness to Drive"): "Would you drive in your current state right now?"

    Time frame: Up to 24 hours after study drug administration.

  7. Maximum subjective feeling state of VAS "Confidence in Driving" after Δ9-THC administration alone or in combination with alcohol compared to placebo.

    Maximum subjective feeling state of VAS "Confidence in Driving" after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to placebo will be measured by the VAS question (VAS Confidence in Driving): "How confident are you in your driving ability?"

    Time frame: Up to 24 hours after study drug administration.

  8. Maximum subjective feeling state of VAS "Liking" after Δ9-THC administration alone or in combination with alcohol compared to placebo.

    Maximum subjective feeling state of VAS "Liking" after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to placebo will be measured by the VAS question (VAS Liking): "How much do you like the drug effects right now?"

    Time frame: Up to 24 hours after study drug administration.

  9. Maximum subjective feeling state of VAS "High" after Δ9-THC administration alone or in combination with alcohol compared to placebo.

    Maximum subjective feeling state of VAS "High" after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to placebo will be measured by the VAS question (VAS High): "How high do you feel right now?"

    Time frame: Up to 24 hours after study drug administration.

  10. Maximum subjective feeling state of VAS "Bad Effects" after Δ9-THC administration alone or in combination with alcohol compared to placebo.

    Maximum subjective feeling state of VAS "Bad Effects" after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to placebo will be measured by the VAS question (VAS Bad Effects): "Are you feeling any bad effects right now?"

    Time frame: Up to 24 hours after study drug administration.

  11. Maximum subjective feeling state of VAS "Drowsy" after Δ9-THC administration alone or in combination with alcohol compared to placebo.

    Maximum subjective feeling state of VAS "Drowsy" after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to placebo will be measured by the VAS question (VAS Drowsy): "How drowsy do you feel right now?"

    Time frame: Up to 24 hours after study drug administration.

  12. Maximum subjective feeling state of VAS "Take Drug Again" after Δ9-THC administration alone or in combination with alcohol compared to placebo.

    Maximum subjective feeling state of VAS "Take Drug Again" after Δ9-THC administration (5 mg, 10 mg, 5 mg with alcohol, 10 mg with alcohol) compared to placebo will be measured by the VAS question (VAS Take Drug Again): "How likely are you to take this drug again?"

    Time frame: Up to 24 hours after study drug administration.

07

Study locations

2 sites
  • Spaulding Clinical Research
    West Bend, Wisconsin 53095, United States
  • Spaulding Clinical
    West Bend, Wisconsin 53095, United States
08

References and documents

Publications

  • Cleveland Clinic. Blood Alcohol Content (BAC). https://my.clevelandclinic.org/health/diagnostics/22689-blood-alcohol-content-bac
  • Dronabinol (Marinol®) capsule label obtained from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018651s033lbl.pdf
  • Zamarripa CA, Novak MD, Weerts EM, Vandrey R, Spindle TR. The effects of oral and vaporized cannabis alone, and in combination with alcohol, on driving performance using the STISIM driving simulator: A two-part, double-blind, double-dummy, placebo-controlled, randomized crossover clinical laboratory protocol. Front Pharmacol. 2022 Sep 6;13:964749. doi: 10.3389/fphar.2022.964749. eCollection 2022. PubMed 36147331 ↗
  • Garrisson H, Scholey A, Verster JC, Shiferaw B, Benson S. Effects of alcohol intoxication on driving performance, confidence in driving ability, and psychomotor function: a randomized, double-blind, placebo-controlled study. Psychopharmacology (Berl). 2022 Dec;239(12):3893-3902. doi: 10.1007/s00213-022-06260-z. Epub 2022 Nov 2. PubMed 36322184 ↗
  • Weerts EM, Wand GS, Maher B, Xu X, Stephens MA, Yang X, McCaul ME. Independent and Interactive Effects of OPRM1 and DAT1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers. Alcohol Clin Exp Res. 2017 Jun;41(6):1093-1104. doi: 10.1111/acer.13384. Epub 2017 Apr 26. PubMed 28376280 ↗
  • Fisher HR, Simpson RI, Kapur BM. Calculation of blood alcohol concentration (BAC) by sex, weight, number of drinks and time. Can J Public Health. 1987 Sep-Oct;78(5):300-4. No abstract available. PubMed 3690446 ↗
  • Veldstra JL, Bosker WM, de Waard D, Ramaekers JG, Brookhuis KA. Comparing treatment effects of oral THC on simulated and on-the-road driving performance: testing the validity of driving simulator drug research. Psychopharmacology (Berl). 2015 Aug;232(16):2911-9. doi: 10.1007/s00213-015-3927-9. Epub 2015 May 10. PubMed 25957748 ↗
  • Brooks-Russell A, Brown T, Friedman K, Wrobel J, Schwarz J, Dooley G, Ryall KA, Steinhart B, Amioka E, Milavetz G, Sam Wang G, Kosnett MJ. Simulated driving performance among daily and occasional cannabis users. Accid Anal Prev. 2021 Sep;160:106326. doi: 10.1016/j.aap.2021.106326. Epub 2021 Aug 14. PubMed 34403895 ↗
  • Hartman RL, Huestis MA. Cannabis effects on driving skills. Clin Chem. 2013 Mar;59(3):478-92. doi: 10.1373/clinchem.2012.194381. Epub 2012 Dec 7. PubMed 23220273 ↗
  • Bosker WM, Kuypers KP, Theunissen EL, Surinx A, Blankespoor RJ, Skopp G, Jeffery WK, Walls HC, van Leeuwen CJ, Ramaekers JG. Medicinal Delta(9) -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction. 2012 Oct;107(10):1837-44. doi: 10.1111/j.1360-0443.2012.03928.x. Epub 2012 Jul 12. PubMed 22553980 ↗
  • Schnakenberg Martin AM, Flynn LT, Sefik E, Luddy C, Cortes-Briones J, Skosnik PD, Pittman B, Ranganathan M, D'Souza DC. Preliminary study of the interactive effects of THC and ethanol on self-reported ability and simulated driving, subjective effects, and cardiovascular responses. Psychopharmacology (Berl). 2023 Jun;240(6):1235-1246. doi: 10.1007/s00213-023-06356-0. Epub 2023 Apr 12. PubMed 37045988 ↗
  • Manning B, Hayley AC, Catchlove S, Shiferaw B, Stough C, Downey LA. Effect of CannEpil(R) on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial. J Psychopharmacol. 2023 May;37(5):472-483. doi: 10.1177/02698811231170360. Epub 2023 May 2. PubMed 37129083 ↗
  • Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, Gorelick DA, Gaffney G, Huestis MA. Cannabis effects on driving lateral control with and without alcohol. Drug Alcohol Depend. 2015 Sep 1;154:25-37. doi: 10.1016/j.drugalcdep.2015.06.015. Epub 2015 Jun 23. PubMed 26144593 ↗
  • Hartley S, Simon N, Cardozo B, Larabi IA, Alvarez JC. Can inhaled cannabis users accurately evaluate impaired driving ability? A randomized controlled trial. Front Public Health. 2023 Nov 22;11:1234765. doi: 10.3389/fpubh.2023.1234765. eCollection 2023. PubMed 38074719 ↗
  • Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Effect of Cannabidiol and Delta9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. JAMA. 2020 Dec 1;324(21):2177-2186. doi: 10.1001/jama.2020.21218. PubMed 33258890 ↗

Individual participant data

Plan to share: Yes — Plan is to make data from the study publicly available as part of a manuscript publication. In addition, the protocol and statistical analysis plan will be made available online at this site as well as with any eventual publications.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The data will become available at the time of manuscript publication.

Access criteria: No restrictions

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2025 to primary completion in Jun 2026, 5 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Apr 2026 → Jun 2026 and completion Apr 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2025
First posted
Sep 16, 2025
StartActual
Dec 29, 2025
Primary completionActual
Jun 19, 2026was Apr 2026
CompletionActual
Jun 19, 2026was Apr 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 30, 2026
Primary completion
Apr 14, 2026→Jun 19, 2026 (actual)
Sep 30, 2026
Study completion
Apr 14, 2026→Jun 19, 2026 (actual)
Sep 30, 2026
Eligibility
1 inclusion criterion edited, 1 added; 2 exclusion criteria edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • AddedSubjects who meet all the following inclusion criteria will be eligible to participate in the study:
  • EditedMale subjects must agree to practice 2 effective methods of birth control (as determined by the investigator or designee) beginning at check-in (Day -1) until at least 3 months after the last dose of study drug. Subject must also agree to inform female partner(s) about participation in the study and ensure they are using a highly effective form of contraception (e.g., hormonal birth control or copper IUD). Male subjects may not donate sperm for 90 days after3 months following the endlast dose of the studystudy drug.
Exclusion criteria
  • AddedSubjects who meet any of the following exclusion criteria will not be eligible to participate in the study:
  • EditedSubject has a history of consumingSubjects will be excluded if they meet criteria for alcohol use disorder based on alcohol abuse screening or exceed monthly consumption thresholds (no more than 8 standard drinks/month for females and no more than 16 standard drinks/month for males and no more than 14 units of alcoholic beveragesstandard drinks per week within 6 months before Screening), or has a history of alcohol use disorder or drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12 ounces of beer, 5 ounces of wine, or 1.5 ounce of spirits/hard liquor).
  • RemovedSubject tests positive for potential active alcohol use disorder (as determined by a score of 3 or greater on the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C).
  • EditedSubject has a mean systolic blood pressure <90 or >140 mmHg or a mean diastolic blood pressure <50 or >90 mmHg at either screening or check-ins, unless determined not clinically significant per investigator. Blood pressure will be measured after the subject has been resting in a sitting position for approximately 5 minutes. Two blood pressure repeats will be permitted in instances where initial measures out of normal range and the average of the three readings will be used to determine eligibility.
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Completed
    Primary completion Apr 14, 2026→Jun 19, 2026 (now actual)
    Study completion Apr 14, 2026→Jun 19, 2026 (now actual)
    Eligibility 1 inclusion criterion edited, 1 added; 2 exclusion criteria edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • AddedSubjects who meet all the following inclusion criteria will be eligible to participate in the study:
    • EditedMale subjects must agree to practice 2 effective methods of birth control (as determined by the investigator or designee) beginning at check-in (Day -1) until at least 3 months after the last dose of study drug. Subject must also agree to inform female partner(s) about participation in the study and ensure they are using a highly effective form of contraception (e.g., hormonal birth control or copper IUD). Male subjects may not donate sperm for 90 days after3 months following the endlast dose of the studystudy drug.
    Exclusion criteria
    • AddedSubjects who meet any of the following exclusion criteria will not be eligible to participate in the study:
    • EditedSubject has a history of consumingSubjects will be excluded if they meet criteria for alcohol use disorder based on alcohol abuse screening or exceed monthly consumption thresholds (no more than 8 standard drinks/month for females and no more than 16 standard drinks/month for males and no more than 14 units of alcoholic beveragesstandard drinks per week within 6 months before Screening), or has a history of alcohol use disorder or drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12 ounces of beer, 5 ounces of wine, or 1.5 ounce of spirits/hard liquor).
    • RemovedSubject tests positive for potential active alcohol use disorder (as determined by a score of 3 or greater on the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C).
    • EditedSubject has a mean systolic blood pressure <90 or >140 mmHg or a mean diastolic blood pressure <50 or >90 mmHg at either screening or check-ins, unless determined not clinically significant per investigator. Blood pressure will be measured after the subject has been resting in a sitting position for approximately 5 minutes. Two blood pressure repeats will be permitted in instances where initial measures out of normal range and the average of the three readings will be used to determine eligibility.
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07176208
Lead sponsor
Food and Drug Administration (FDA)
Collaborators
Spaulding Clinical Research LLC
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Dec 29, 2025
Primary completion
Jun 19, 2026
Completion
Jun 19, 2026
Last update
Sep 30, 2026

Study contacts

Melanie Fein, MD
principal investigator · Spaulding Clinical Research LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion